The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of CNS cancers. Integrated histopathologic and molecular characterization of brain tumors such as gliomas should be standard practice. This article describes NCCN Guidelines recommendations for WHO grade I, II, III, and IV gliomas. Treatment of brain metastases, the most common intracranial tumors in adults, is also described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationOstrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationAndrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Glioma Groups Based on 1p/19q,IDH, and TERT Promoter Mutations in Tumors
Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M. L., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,982
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Barker, F. G., Deming, R., Burri, S. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9839 · Cited by 1,671
Walker, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,667
Shaw, E., Scott, C., Souhami, L., Dinapoli, R., Kline, R., Loeffler, J., & Farnan, N. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00507-6 · Cited by 1,608
Self-citationSchouten, L. J., Rutten, J., Huveneers, H. A. M., & Twijnstra, A. (2002) · Cancer · doi:10.1002/cncr.10541 · Cited by 1,590
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., Yamanaka, K., Sato, Y., Jokura, H., Yomo, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70061-0 · Cited by 1,447
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Self-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,321
Self-citationMalmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Brown, P. D., Ballman, K. V., Cerhan, J. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30441-2 · Cited by 1,220
Ostrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationCairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Gondi, V., Pugh, S. L., Tome, W. A., Caine, C., Corn, B., Kanner, A., Rowley, H., Kundapur, V., DeNittis, A., Greenspoon, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2909 · Cited by 1,148
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery
Vecht, C. J., Haaxma‐Reiche, H., Noordijk, E. M., Padberg, G. W., Voormolen, J. H. C., Hoekstra, F. H., Tans, J. T. J., Lambooij, N., Metsaars, J. A. L., Wattendorff, A. R., et al. (1993) · Annals of Neurology · doi:10.1002/ana.410330605 · Cited by 1,049
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 958
Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Self-citationStupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Brown, P. D., Gondi, V., Pugh, S., Tome, W. A., Wefel, J. S., Armstrong, T. S., Bovi, J. A., Robinson, C., Konski, A., Khuntia, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02767 · Cited by 846
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Self-citationFranz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Mahajan, A., Ahmed, S., McAleer, M. F., Weinberg, J. S., Li, J., Brown, P., Settle, S., Prabhu, S. S., Lang, F. F., Levine, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30414-x · Cited by 789
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Davies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Shaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.126 · Cited by 730
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., Moore, B., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 711
Karim, A. B. M. F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H. J. M., Thomas, D. G. T., Mascarenhas, F., Horiot, J. C., Parvinen, L. M., van Reijn, M., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00352-5 · Cited by 694
Mintz, A. H., Kestle, J. R. W., Rathbone, M. P., Gaspar, L. E., Hugenholtz, H., Fisher, B., Duncan, G. G., Skingley, P., Foster, G., & Levine, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961001)78:7<1470::aid-cncr14>3.0.co;2-x · Cited by 685
Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L., Satouchi, M., Chu, Q., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 645
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Soffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Self-citationFrequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Self-citationHerrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.-D., Krex, D., Grauer, O., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 568
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
McGirt, M. J., Chaichana, K. L., Attenello, F. J., Weingart, J. D., Than, K., Burger, P. C., Olivi, A., Brem, H., & Quinoñes-Hinojosa, A. (2008) · Neurosurgery · doi:10.1227/01.neu.0000325729.41085.73 · Cited by 533
Self-citationYan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
Seizure characteristics and control following resection in 332 patients with low-grade gliomas
Chang, E. F., Potts, M. B., Keles, G. E., Lamborn, K. R., Chang, S. M., Barbaro, N. M., & Berger, M. S. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/2/0227 · Cited by 526
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Self-citationcIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figrarella-Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 520
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Minniti, G., Scaringi, C., Paolini, S., Lanzetta, G., Romano, A., Cicone, F., Osti, M., Enrici, R. M., & Esposito, V. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.03.013 · Cited by 478
Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
Self-citationReuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D. T. W., Hovestadt, V., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1370-3 · Cited by 449
Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Stat, M., Nesbakken, R., Hatlevoll, R., Lindgren, M., Brun, A., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810215)47:4<649::aid-cncr2820470405>3.0.co;2-w · Cited by 424
Limitations of stereotactic biopsy in the initial management of gliomas
Jackson, R. J., Fuller, G. N., Abi-Said, D., Lang, F. F., Gokaslan, Z. L., Shi, W. M., Wildrick, D. M., & Sawaya, R. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.3.193 · Cited by 416
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Levin, V. A., Silver, P., Hannigan, J., Wara, W. M., Gutin, P. H., Davis, R. L., & Wilson, C. B. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90096-3 · Cited by 401
Lombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Self-citationArita, H., Narita, Y., Fukushima, S., Tateishi, K., Matsushita, Y., Yoshida, A., Miyakita, Y., Ohno, M., Collins, V. P., Kawahara, N., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1141-6 · Cited by 376
Multidisciplinary Management of Brain Metastases
Eichler, A. F., & Loeffler, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-884 · Cited by 366
Self-citationScale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
Park, J. K., Hodges, T., Arko, L., Shen, M., Dello Iacono, D., McNabb, A., Olsen Bailey, N., Kreisl, T. N., Iwamoto, F. M., Sul, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0582 · Cited by 359
Shaw, E. G., Wang, M., Coons, S. W., Brachman, D. G., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., & Mehta, M. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8598 · Cited by 355
Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
Self-citationFreedman, R. A., Gelman, R. S., Anders, C. K., Melisko, M. E., Parsons, H. A., Cropp, A. M., Silvestri, K., Cotter, C. M., Componeschi, K. P., Marte, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01511 · Cited by 341
Roa, W., Kepka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., Guedes de Castro, D., Dyttus-Cebulok, K., Drodge, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6606 · Cited by 340
Pleomorphic xanthoastrocytoma: What do we really know about it?
Giannini, C., Scheithauer, B. W., Burger, P. C., Brat, D. J., Wollan, P. C., Lach, B., & O'Neill, B. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9<2033::aid-cncr22>3.0.co;2-z · Cited by 335
Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme
Barker, F. G., Chang, S. M., Gutin, P. H., Malec, M. K., McDermott, M. W., Prados, M. D., & Wilson, C. B. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00013 · Cited by 330
Radiation therapy in the management of low-grade supratentorial astrocytomas
Shaw, E. G., Daumas-Duport, C., Scheithauer, B. W., Gilbertson, D. T., O'Fallon, J. R., Earle, J. D., Laws, E. R., & Okazaki, H. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.70.6.0853 · Cited by 326
Shaw, E. G., Berkey, B., Coons, S. W., Bullard, D., Brachman, D., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/109/11/0835 · Cited by 324
Pekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Epidemiology of Metastatic Brain Tumors
Fox, B. D., Cheung, V. J., Patel, A. J., Suki, D., & Rao, G. (2011) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2010.08.007 · Cited by 317
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Characteristics of H3 K27M-mutant gliomas in adults
Meyronet, D., Esteban-Mader, M., Bonnet, C., Joly, M.-O., Uro-Coste, E., Amiel-Benouaich, A., Forest, F., Rousselot-Denis, C., Burel-Vandenbos, F., Bourg, V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now274 · Cited by 279
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Sahm, F., Reuss, D., Koelsche, C., Capper, D., Schittenhelm, J., Heim, S., Jones, D. T. W., Pfister, S. M., Herold-Mende, C., Wick, W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1326-7 · Cited by 272
Subependymal giant cell tumors in tuberous sclerosis complex
Goh, S., Butler, W., & Thiele, E. A. (2004) · Neurology · doi:10.1212/01.wnl.0000142039.14522.1a · Cited by 262
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f9c5e · Cited by 260
Arita, H., Yamasaki, K., Matsushita, Y., Nakamura, T., Shimokawa, A., Takami, H., Tanaka, S., Mukasa, A., Shirahata, M., Shimizu, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0351-2 · Cited by 252
BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma
Hawkins, C., Walker, E., Mohamed, N., Zhang, C., Jacob, K., Shirinian, M., Alon, N., Kahn, D., Fried, I., Scheinemann, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0034 · Cited by 250
Variations in the History and Survival of Patients with, Supratentorial Low-grade Astrocytomas
Piepmeier, J., Susan Christopher, R. N., Spencer, D., Byrne, T., Kim, J., Knisel, J. P., Lacy, J., Tsukerman, L., & Makuch, R. (1996) · Neurosurgery · doi:10.1097/00006123-199605000-00002 · Cited by 249
Pleomorphic Xanthoastrocytoma: Natural History and Long‐Term Follow‐Up
Ida, C. M., Rodriguez, F. J., Burger, P. C., Caron, A. A., Jenkins, S. M., Spears, G. M., Aranguren, D. L., Lachance, D. H., & Giannini, C. (2015) · Brain Pathology · doi:10.1111/bpa.12217 · Cited by 246
Cabrera, A. R., Kirkpatrick, J. P., Fiveash, J. B., Shih, H. A., Koay, E. J., Lutz, S., Petit, J., Chao, S. T., Brown, P. D., Vogelbaum, M., et al. (2016) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.03.007 · Cited by 246
Self-citationEllingson, B. M., Chung, C., Pope, W. B., Boxerman, J. L., & Kaufmann, T. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2375-2 · Cited by 246
Nabors, L. B., Fink, K. L., Mikkelsen, T., Grujicic, D., Tarnawski, R., Nam, D. H., Mazurkiewicz, M., Salacz, M., Ashby, L., Zagonel, V., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou356 · Cited by 242
Self-citationStereotactic Radiosurgery for the Management of Brain Metastases
Suh, J. H. (2010) · New England Journal of Medicine · doi:10.1056/nejmct0806951 · Cited by 240
Korshunov, A., Capper, D., Reuss, D., Schrimpf, D., Ryzhova, M., Hovestadt, V., Sturm, D., Meyer, J., Jones, C., Zheludkova, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1493-1 · Cited by 236
Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now133 · Cited by 227
Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., Yomo, S., Aiyama, H., Higuchi, Y., Shuto, T., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1271 · Cited by 223
Self-citationBell, E. H., Zhang, P., Shaw, E. G., Buckner, J. C., Barger, G. R., Bullard, D. E., Mehta, M. P., Gilbert, M. R., Brown, P. D., Stelzer, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02983 · Cited by 219
MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Everhard, S., Kaloshi, G., Crinière, E., Benouaich‐Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang‐Xuan, K., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21044 · Cited by 215
Tsien, C., Galbán, C. J., Chenevert, T. L., Johnson, T. D., Hamstra, D. A., Sundgren, P. C., Junck, L., Meyer, C. R., Rehemtulla, A., Lawrence, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3971 · Cited by 214
Self-citationMolecular pathology of tumors of the central nervous system
Kristensen, B. W., Priesterbach-Ackley, L. P., Petersen, J. K., & Wesseling, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz164 · Cited by 213
Roth, J., Roach, E. S., Bartels, U., Jóźwiak, S., Koenig, M. K., Weiner, H. L., Franz, D. N., & Wang, H. Z. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.017 · Cited by 212
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
Tsao, M. N., Xu, W., Wong, R. K., Lloyd, N., Laperriere, N., Sahgal, A., Rakovitch, E., & Chow, E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003869.pub4 · Cited by 202
Taphoorn, M. J. B., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S., Toms, S. A., Honnorat, J., Chen, T. C., Sroubek, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5082 · Cited by 201
Nicholson, H. S., Kretschmar, C. S., Krailo, M., Bernstein, M., Kadota, R., Fort, D., Friedman, H., Harris, M. B., Tedeschi‐Blok, N., Mazewski, C., et al. (2007) · Cancer · doi:10.1002/cncr.22961 · Cited by 196
Soliman, H., Ruschin, M., Angelov, L., Brown, P. D., Chiang, V. L. S., Kirkpatrick, J. P., Lo, S. S., Mahajan, A., Oh, K. S., Sheehan, J. P., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.09.047 · Cited by 195
Wiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Adriaensen, M. E. A. P. M., Schaefer‐Prokop, C. M., Stijnen, T., Duyndam, D. A. C., Zonnenberg, B. A., & Prokop, M. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02567.x · Cited by 187
Bell, E. H., Zhang, P., Fisher, B. J., Macdonald, D. R., McElroy, J. P., Lesser, G. J., Fleming, J., Chakraborty, A. R., Liu, Z., Becker, A. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1977 · Cited by 182
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70489-9 · Cited by 179
Clarke, J. L., Iwamoto, F. M., Sul, J., Panageas, K., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 179
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 172
Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 166
Self-citationBlumenthal, D. T., Gorlia, T., Gilbert, M. R., Kim, M. M., Nabors, B., Mason, W. P., Hegi, M. E., Zhang, P., Golfinopoulos, V., Perry, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox025 · Cited by 166
Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163
Fisher, B. J., Hu, C., Macdonald, D. R., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner-Wasik, M., Bahary, J.-P., Liu, J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.012 · Cited by 163
Hegi, M. E., Genbrugge, E., Gorlia, T., Stupp, R., Gilbert, M. R., Chinot, O. L., Nabors, B., Jones, G., Criekinge, W. V., Straub, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3181 · Cited by 162
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
Soffietti, R., Rudà, R., Bradac, G. B., & Schiffer, D. (1998) · Neurosurgery · doi:10.1097/00006123-199811000-00035 · Cited by 161
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Kesari, S., Schiff, D., Drappatz, J., LaFrankie, D., Doherty, L., Macklin, E. A., Muzikansky, A., Santagata, S., Ligon, K. L., Norden, A. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0888 · Cited by 161
Self-citationAnti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 159
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
Leeper, H. E., Caron, A. A., Decker, P. A., Jenkins, R. B., Lachance, D. H., & Giannini, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4497 · Cited by 158
Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis
Kazmi, F., Soon, Y. Y., Leong, Y. H., Koh, W. Y., & Vellayappan, B. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03064-0 · Cited by 158
Daniels, T. B., Brown, P. D., Felten, S. J., Wu, W., Buckner, J. C., Arusell, R. M., Curran, W. J., Abrams, R. A., Schiff, D., & Shaw, E. G. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.003 · Cited by 151
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
Horbinski, C., Nikiforova, M. N., Hagenkord, J. M., Hamilton, R. L., & Pollack, I. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos077 · Cited by 149
Self-citationChang, W. S., Kim, H. Y., Chang, J. W., Park, Y. G., & Chang, J. H. (2010) · Journal of neurosurgery · doi:10.3171/2010.8.gks10994 · Cited by 145
Gorovets, D. J., Kannan, K. S., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., Pentsova, E. I., Heguy, A., Jhanwar, S. C., Mellinghoff, I. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2977 · Cited by 145
Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K. A., Zheng, M., Dimery, I. W., & Friedman, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2010b · Cited by 144
Self-citationTuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations
Franz, D. N., Bissler, J. J., & McCormack, F. X. (2010) · Neuropediatrics · doi:10.1055/s-0030-1269906 · Cited by 141
Schiff, D., van den Bent, M. J., Vogelbaum, M. A., Wick, W., Miller, C. R., TAPHOORN, M. J. B., Pope, W. B., Brown, P. D., Platten, M., Jalali, R., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz033 · Cited by 140
Self-citationRoelz, R., Strohmaier, D., Jabbarli, R., Kraeutle, R., Egger, K., Coenen, V. A., Weyerbrock, A., & Reinacher, P. C. (2016) · Scientific Reports · doi:10.1038/srep32286 · Cited by 137
Gorlia, T., Wu, W., Wang, M., Baumert, B. G., Mehta, M. P., Buckner, J. C., Shaw, E., Brown, P. D., Stupp, R., Galanis, E., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not117 · Cited by 135
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 134
Glas, M., Hertler, C., Rieger, J., Wiewrodt, D., Bähr, O., Steinbach, J. P., Wick, W., Kortmann, R., Reifenberger, G., Weller, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2195 · Cited by 134
Outcomes Following Proton Therapy for Pediatric Low-Grade Glioma
Indelicato, D. J., Rotondo, R. L., Uezono, H., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.01.078 · Cited by 132
Wahl, M. T., Phillips, J. J., Molinaro, A. M., Lin, Y., Perry, A., Haas-Kogan, D. A., Costello, J., Dayal, M., Butowski, N. A., Clarke, J. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now176 · Cited by 131
Self-citationManagement of low-grade glioma: a systematic review and meta-analysis
Brown, T. J., Bota, D. A., van den Bent, M. J., Brown, P. D., Maher, E. A., Aregawi, D. G., Liau, L. M., Buckner, J. C., Weller, M., Berger, M. S., et al. (2018) · Neuro-Oncology Practice · doi:10.1093/nop/npy034 · Cited by 130
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122
Penman, C. L., Faulkner, C., Lowis, S. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00054 · Cited by 119
Jaeckle, K. A., Ballman, K. V., van den Bent, M., Giannini, C., Galanis, E., Brown, P. D., Jenkins, R. B., Cairncross, J. G., Wick, W., Weller, M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noaa168 · Cited by 119
ToBRAFor Not toBRAF: Is That Even a Question Anymore?
Horbinski, C. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318279f3db · Cited by 118
Self-citationPetrelli, F., Ghidini, M., Lonati, V., Tomasello, G., Borgonovo, K., Ghilardi, M., Cabiddu, M., & Barni, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.024 · Cited by 115
Farris, M. K., McTyre, E., Cramer, C. K., Hughes, R. T., Randolph, D. M., Ayala-Peacock, D. N., Bourland, J. D., Ruiz, J., Watabe, K., Laxton, A. W., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.01.201 · Cited by 114
Hong, A., Fogarty, G. B., Jacobsen, K. D., Burmeister, B. H., Lo, S., Haydu, L. E., Vardy, J. L., Nowak, A. K., Dhillon, H. M., Ahmed, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01414 · Cited by 113
Balañá, C., Salgado, M. Á. V., Sepúlveda-Sánchez, J. M., Mesía, C., Barco, S. D., Pineda, E., Muñoz-Langa, J., Estival, A., Peñas, R. D. L., Fuster, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa107 · Cited by 111
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M. O., & Nikkhah, G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-30 · Cited by 107
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1002 · Cited by 99
Thirty years' experience with Gamma Knife surgery for metastases to the brain
Karlsson, B., Hanssens, P. E. J., Wolff, R. F., Söderman, M., Lindquist, C., & Beute, G. N. (2009) · Journal of neurosurgery · doi:10.3171/2008.10.jns08214 · Cited by 95
Brain Metastasis: Opportunities in Basic and Translational Research
Maher, E. A., Mietz, J. A., Arteaga, C. L., DePinho, R. A., & Mohla, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4347 · Cited by 92
PCV chemotherapy for recurrent glioblastoma
Schmidt, F., Fischer, J., Herrlinger, U., Dietz, K., DICHGANS, J., & Weller, M. (2006) · Neurology · doi:10.1212/01.wnl.0000197792.73656.c2 · Cited by 89
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas
Triebels, V. H. J. M., TAPHOORN, M. J. B., Brandes, A. A., Menten, J. J., Frénay, M., Tosoni, A., Kros, J. M., Stege, E. M. B., Enting, R. H., Allgeier, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000137049.65631.db · Cited by 89
Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection
Nitta, M., Muragaki, Y., Maruyama, T., Ikuta, S., Komori, T., Maebayashi, K., Iseki, H., Tamura, M., Saito, T., Okamoto, S., et al. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14651 · Cited by 89
Breaking down the epidemiology of brain cancer
Gould, J. (2018) · Nature · doi:10.1038/d41586-018-06704-7 · Cited by 88
Minniti, G. C., Scaringi, C., Lanzetta, G., Terrenato, I., Esposito, V., Arcella, A., Pace, A., Giangaspero, F., Bozzao, A., & Enrici, R. M. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.013 · Cited by 84
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Brandes, A. A. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-005 · Cited by 82
Arevalo, O., Soto, C., Rabiei, P., Kamali, A., Ballester, L. Y., Esquenazi, Y., Zhu, J., & Riascos, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00460 · Cited by 79
Outcomes in Reoperated Low-Grade Gliomas
Ramakrishna, R. R., Hebb, A. O., Barber, J. K., Rostomily, R., & Silbergeld, D. L. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000753 · Cited by 78
Chang, S. M., Zhang, J., Cairncross, J. G., Gilbert, M. R., Bahary, J.-P., Dolinskas, C. A., Chakravarti, A., Aldape, K., Bell, E. H., Schiff, D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now236 · Cited by 78
Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas
Fink, J. R., Born, D. E., & Chamberlain, M. C. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0157-1 · Cited by 76
Bevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma
Chamberlain, M. C., & Johnston, S. K. (2009) · Cancer · doi:10.1002/cncr.24179 · Cited by 71
Stereotactic Radiosurgical Treatment of Cerebral Metastases Arising From Breast Cancer
Akyürek, S., Chang, E. L., Mahajan, A., et al. (2007) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000258365.50975.f6 · Cited by 68
Cited by
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Berger, T. R., Wen, P. Y., Lang-Orsini, M., & Chukwueke, U. N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2844 · Cited by 297
Self-citationPouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
Shi, W., Blumenthal, D. T., Oberheim Bush, N. A., Kebir, S., Lukas, R. V., Muragaki, Y., Zhu, J.-J., & Glas, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03540-6 · Cited by 61
Metadata
- Authors
- Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., Horbinski, C., Junck, L., Kaley, T., Kumthekar, P., Loeffler, J. S., Mrugala, M. M., Nagpal, S., Pandey, M., Parney, I., Peters, K., Puduvalli, V. K., Robins, I., Rockhill, J., Rusthoven, C., Shonka, N., Shrieve, D. C., Swinnen, L. J., Weiss, S., Wen, P. Y., Willmarth, N. E., Bergman, M. A., & Darlow, S. D.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2020-11
- Volume
- 18
- Issue
- 11
- Pages
- 1537-1570
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3097339274
- Cited by
- 539
- References
- 236
- FWCI
- 36.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.